South Korea approves Jascayd nerandomilast for idiopathic pulmonary fibrosis
South Korea has authorised Jascayd (nerandomilast) for idiopathic pulmonary fibrosis, providing a new national treatment option for patients with progressive lung scarring.
The Ministry of Food and Drug Safety granted marketing approval for the phosphodiesterase-4 inhibitor following an expedited review under its Global Innovative Products on Fast Track programme.
The decision represents a separate South Korean authorisation from Jascayd's earlier Saudi approval and expands the drug's regulatory footprint in a disease with substantial unmet treatment needs.
Field | Content |
Article Type | Approvals |
Drug Name | Jascayd |
Generic Name | Nerandomilast |
Regulatory Authority | South Korea Ministry of Food and Drug Safety |
Regulatory Decision | National marketing authorisation |
Indication | Idiopathic pulmonary fibrosis |
Therapeutic Area | Respiratory medicine; fibrotic lung disease |
Therapeutic Modality | Small-molecule phosphodiesterase-4 inhibitor |
Mechanism of Action | Phosphodiesterase-4 inhibition |
Regulatory Pathway | Global Innovative Products on Fast Track programme |
Approval Date | 15 October 2026 |
Geography | South Korea |
Company | Not confirmed in the supplied summary |
Patient Population | Patients with idiopathic pulmonary fibrosis; specific label restrictions not confirmed in supplied summary |
Clinical Evidence | Specific study results not provided in supplied summary |
What Happened | South Korea's Ministry of Food and Drug Safety approved Jascayd nerandomilast for idiopathic pulmonary fibrosis. |
Why It Matters | The authorisation introduces another treatment option for a progressive fibrotic lung disease and broadens the availability of a therapy with a different mechanism from established antifibrotics. |
Regulatory Context | The decision followed expedited review and is distinct from the Saudi SFDA approval previously covered by NEON. |
Key Takeaway | Jascayd has received a new national marketing authorisation in South Korea for idiopathic pulmonary fibrosis. |
What to Watch | Commercial launch timing, reimbursement decisions, prescribing information, clinical adoption and additional territorial approvals. |
Primary Source | Seoul Economic Daily |
Relevant Date | 15 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments